Oramed Pharmaceuticals Inc. entered into an extension agreement with Scilex Holding Company to extend the payment obligations of approximately $36.2 million in principal and interest across two senior secured promissory and convertible notes. Scilex will make cash payments of $0.5 million received on June 25, 2026, $5 million by July 31, 2026, and the remaining balance by September 30, 2026. If Scilex fails to pay by the due date, the first $1.5 million received will be treated as an extension fee and the remaining obligations will be settled via Scilex common stock. Oramed Pharmaceuticals Inc. is a pharmaceutical company that develops and commercializes specialty pharmaceutical products.